Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 741.91

-1.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Silverman who wrote (61)	3/26/1997 2:14:00 AM
From: Miljenko Zuanic	of 3559

Story on BDNF is not over. Currently, in Germany (this is on Jan. 15), it is in small phase I trials for ALS intrathecaly administrated. Back, when I spooked with AMGN, they sad that excalating dosage are still ongoing and results will be out in several months. REGN clearly demonstrate (in research and preclinical) that BDNF do promote motor neurons ( responsible for breading) regeneration and survive. The results in phase II (positive but small) mislead phase III (subcutaneous delivery). IMO problem is in blood-brain-barrier. BDNF and NT-3 have protective effects in diabetic and chemotherapeutic neuropathy. Results from phase I/II or II should be out by 2Q end. But, GNE is already ahead from AMGN/REGN and I do not know how to value this program. Trouble with CNTF was in severe side effects when they increase dosage. AMGN started (Jan.) intrathecal CNTF and GDNF delivery for ALS (again Medtronic)-small phase I. CTII already proved that its CNTF implants works in ALS, and phase II data should be out by 3Q/4Q. This is real mystery for me, because AMGN have right on CNTF and REGN on CNTF-receptor. How will CTII license CNTF is BIG QUESTION!! mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next